Advertisement

Topics

PubMed Journals Articles About "Mineralocorticoid Receptor In The Treatment Of Severe Depression" RSS

18:33 EST 22nd January 2019 | BioPortfolio

Mineralocorticoid Receptor In The Treatment Of Severe Depression PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Mineralocorticoid Receptor In The Treatment Of Severe Depression articles that have been published worldwide.

More Information about "Mineralocorticoid Receptor In The Treatment Of Severe Depression" on BioPortfolio

We have published hundreds of Mineralocorticoid Receptor In The Treatment Of Severe Depression news stories on BioPortfolio along with dozens of Mineralocorticoid Receptor In The Treatment Of Severe Depression Clinical Trials and PubMed Articles about Mineralocorticoid Receptor In The Treatment Of Severe Depression for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Mineralocorticoid Receptor In The Treatment Of Severe Depression Companies in our database. You can also find out about relevant Mineralocorticoid Receptor In The Treatment Of Severe Depression Drugs and Medications on this site too.

Showing "Mineralocorticoid Receptor Treatment Severe Depression" PubMed Articles 1–25 of 39,000+

Markers of mineralocorticoid receptor function: changes over time and relationship to response in patients with major depression.

The renin-angiotensin-aldosterone system and its hormone receptors, i.e. the angiotensin and mineralocorticoid receptor (MR), have emerged as important targets for central nervous system disorders and in particular for major depression. We have recently characterized baseline MR function as a predictor for treatment outcome with standard antidepressants. The aims of this study are (i) to characterize how strongly an early biomarker change (after 2 weeks) is related to outcome and (ii) whether these biomarke...


Treatment selection and treatment initialization in guideline-based stepped and collaborative care for depression.

In order to optimize patient allocation, guidelines recommend stepped and collaborative care models (SCM) including low-intensity treatments. The aim of this study is to investigate the implementation of guideline-adherent treatments in a SCM for depression in routine care. We analyzed care provider documentation data of n = 569 patients treated within a SCM. Rates of guideline-adherent treatment selections and initializations as well as accordance between selected and initialized treatment were evaluated f...

Predictive Factors of Response to Mineralocorticoid Receptor Antagonists in non-resolving Central Serous Chorioretinopathy.

To assess the efficacy and safety of mineralocorticoid receptor antagonists (MRA) in the treatment of non-resolving central serous chorioretinopathy (CSC) and identify predictive factors of treatment response.


Ketamine for Treatment-Resistant Depression: A Gateway to Novel Treatment Approaches.

Treatment-resistant depression (TRD) is a disabling and demoralizing phenomenon for patients and clinicians. For many years, treatment for depression has relied on the monoamine theory, with medications limited in efficacy and requiring prolonged use before any therapeutic effects are evident. The current article reviews novel approaches to pharmacological treatment of TRD, including N-methyl-D-aspartate glutamate receptor antagonists and other receptor agonists and antagonists beyond serotonin and norepine...

Mineralocorticoid Receptor Antagonism Treatment for All Patients With ST-Segment Myocardial Infarction?

Mineralocorticoid Receptor Antagonism Treatment for All Patients With ST-Segment Myocardial Infarction?-Reply.

Case Report: Ketamine for Pain and Depression in Advanced Cancer.

Patients with advanced cancer often suffer from both severe pain and severe symptoms of depression. Use of traditional antidepressants is often limited by the short prognosis associated with advanced cancer. We present the case of a patient with neuropathic pain from advanced cancer and severe depression that responded dramatically to an intravenous infusion of ketamine resulting in decreased pain and resolution of severe depression symptoms.

Mineralocorticoid Receptor Antagonism Improves Parenchymal Arteriole Dilation Via a TRPV4-Dependent Mechanism and Prevents Cognitive Dysfunction in Hypertension.

Hypertension and mineralocorticoid receptor activation cause cerebral parenchymal arteriole remodeling; this can limit cerebral perfusion and contribute to cognitive dysfunction. We utilized a mouse model of angiotensin II-induced hypertension to test the hypothesis that mineralocorticoid receptor activation impairs both TRPV4-mediated dilation of cerebral parenchymal arterioles and cognitive function. 16-18-week-old male C57bl/6 mice were treated with angiotensin II (800ng/kg/min) ± the mineralocorticoid ...

Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration.

Choroidal neovascularization (CNV) is a major cause of visual impairment in patients suffering from wet age-related macular degeneration (AMD), particularly when refractory to intraocular anti-VEGF injections. Here we report that treatment with the oral mineralocorticoid receptor (MR) antagonist spironolactone reduces signs of CNV in patients refractory to anti-VEGF treatment. In animal models of wet AMD, pharmacological inhibition of the MR pathway or endothelial-specific deletion of MR inhibits CNV throug...

Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice.

Although beneficial antihypertensive and antialbuminuric effects of steroidal mineralocorticoid receptor (MR) antagonists have been shown, the use of these drugs has been clinically limited in diabetic kidney disease (DKD) because of the high incidence of side effects. Here, we aimed to examine the effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone, on blood pressure and renal injury in high salt-treated type 2 diabetic KK-A mice, a model of human hypertensive DKD. K...

Potential target-organ protection of mineralocorticoid receptor antagonist in acute kidney disease.

Acute kidney disease (AKD), the transition of acute kidney injury to chronic kidney disease, has major clinical significance. Whether mineralocorticoid receptor antagonist will afford target organ protection during this critical stage remains ill-defined.

Mineralocorticoid Receptor Antagonist Utilization in a Nationally Representative Heart Failure With Reduced Ejection Fraction Outpatient Population: A Cross-Sectional Study.

Mineralocorticoid receptor antagonists (MRAs) improve survival among patients with heart failure with reduced ejection fraction (HFrEF); however, studies have identified low utilization rates. No study has evaluated the prevalence and predictors of MRA prescribing in a nationally representative outpatient cohort.

Methylation of the glucocorticoid receptor gene associated with depression in patients with acute coronary syndrome.

The present study investigated the longitudinal effects of NR3C1 1 F exon methylation on the risk of depression following ACS and treatment outcomes.

Genetic variation of the mineralocorticoid receptor gene (MR, NR3C2) is associated with a conceptual endophenotype of "CRF-hypoactivity".

Recently, the "conceptual endophenotype" approach has been proposed as a means to identify subgroups of patients affected by stress-related psychiatric disorders. Conceptual endophenotypes consist of patterns of psychological, biological, and symptomatic elements. We studied a sample of patients seeking help for psychosomatic and stress-related disorders (total N = 469), who were evaluated with a diagnostic instrument that integrates psychological and biological data to derive 13 endophenotypes, or Neur...

BDNF as a biomarker in diagnosis and evaluation of treatment for schizophrenia and depression.

Schizophrenia and major depression disorders, both being of pathological synaptogenesis, are the most common psychiatric disorders worldwide. These diseases, if not treated effectively, may cause suicide and are a serious social and economic challenge. Although schizophrenia and depression can be significantly improved with the second-generation atypical antipsychotics, rising drug resistance has limited their efficacy. Repetitive Transcranial Magnetic Stimulation (rTMS) has appeared to be a promising thera...

The effects of glucocorticoids on depressive and anxiety-like behaviors, mineralocorticoid receptor-dependent cell proliferation regulates anxiety-like behaviors.

Glucocorticoids are vital stress response hormones and facilitate stress coping. However, sustained glucocorticoid exposure is associated with negative effects on brain. The precise role of glucocorticoids in depression and anxiety remains unclear. In the present study, we found that rats exposed to chronic unpredictable stress (CUS) showed anxiety-like behavior but not depressive-like behavior in the absence of glucocorticoid production. It was interesting to find that the level of serotonin (5-HT) and the...

Antidepressant-like Effects of Insulin and IGF-1 are Mediated by IGF-1 Receptors in the Brain.

Depression is associated with uncontrolled diabetes, which indicates a lack of insulin effect, yet the role of the insulin receptor in mediating depression is not clearly established because insulin receptors are not required for glucose entry into the brain. However, insulin receptors are important for brain function since insulin receptor knockout mice have depressive-like activity. Depression and cognitive problems are also associated with low insulin-like growth factor-1 (IGF-1) in the elderly. Rodent s...

Quality of life across domains among individuals with treatment-resistant depression.

Treatment-resistant depression affects millions of people worldwide and is a leading cause of disability and suicide. Studies of treatment-resistant depression outcomes have traditionally focused on depressive symptoms and functional impairment. Quality of life (QoL) has not been well described. We aimed to measure QoL in individuals with treatment-resistant depression and to determine how QoL was related to traditional measures of symptoms and social functioning.

Statin treatment and the risk of depression.

The effect of statin treatment on the risk of developing depression remains unclear. Therefore, we assessed the association between statin treatment and depression in a nationwide register-based cohort study with up to 20 years of follow up.

Serotonin receptors in depression and anxiety: Insights from animal studies.

Serotonin regulates many physiological processes including sleep, appetite, and mood. Thus, serotonergic system is an important target in the treatment of psychiatric disorders, such as major depression and anxiety. This natural neurotransmitter interacts with 7 families of its receptors (5-HT1-7), which cause a variety of pharmacological effects. Using genetically modified animals and selective or preferential agonists and antagonist, numerous studies demonstrated the involvement of almost all serotonin re...

NMDA receptor in the hippocampus alters neurobehavioral phenotypes through inflammatory cytokines in rats with sporadic Alzheimer-like disease.

Many patients with sporadic Alzheimer's disease (AD) suffer from memory impairment, anxiety- and depression. The systemic utility of N-Methyl-d-Aspartate (NMDA) receptor antagonists has been shown to be potential therapeutic target for memory loss in AD. However, there is no evidence that shows whether NMDA receptor antagonists have the same effects when these blockers are directly used within the brain regions including hippocampus. It might be an urgent to further explore the therapeutic role of NMDA rece...

Mineralocorticoid receptor antagonists (MRAs): more attention required (to prescription)!

Trick or treat? Evaluating contributing factors and sex-differences for developmental effects of maternal depression and its treatment.

Maternal depression and treatment with selective serotonin reuptake inhibitors (SSRIs), the most common form of pharmaceutical intervention, can both have an impact on infant development. As such, it is difficult for healthcare providers to recommend a course of treatment to expectant mothers suffering from depression, or to women on antidepressant medication prior to pregnancy. This review will discuss the existing research on the developmental impacts of maternal depression and its treatment with SSRIs, w...

Brain neurokinin-1 receptor availability in never-medicated patients with major depression - A pilot study.

Neurotransmitter substance P (SP) and its preferred neurokinin-1 receptor (NK1R) have been implicated in the treatment of affective and addiction disorders. Despite promising preclinical data on antidepressant action, the clinical trials of NK1R antagonists in major depression have been disappointing. There are no direct in vivo imaging studies on NK1R characteristics in patients with a major depressive disorder (MDD).

"Lithium in the treatment of old age depression. What are the pros and cons?"

Augmentation with lithium is one of the treatment options in therapy-resistant depression. This review presents the current data concerning the use of lithium in elderly patients with unipolar depression.


Advertisement
Quick Search
Advertisement
Advertisement